Volume 71, Issue 5, Pages (May 2017)

Slides:

Advertisements

Similar presentations

Volume 72, Issue 1, Pages (July 2017)

Advertisements

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Prostate cancer mortality as a factor of Gleason score and age at diagnosis in men managed conservatively. (Adapted, with permission, from Albertsen PC.

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Volume 61, Issue 6, Pages (June 2012)

Prostate Cancer 2008: Challenges in Diagnosis and Management

Volume 61, Issue 5, Pages (May 2012)

Volume 60, Issue 5, Pages (November 2011)

Volume 53, Issue 5, Pages (May 2008)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 73, Issue 6, Pages (June 2018)

Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 122, Issue 3, Pages (March 2002)

Prostate Cancer Epidemic in Sight?

Volume 62, Issue 6, Pages (December 2012)

The Global Risk of Bladder Cancer: Let's Just Do Something About It!

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 9, Issue 5, Pages (May 2008)

Volume 68, Issue 5, Pages (November 2015)

Prostate Cancer Detection: A View of the Future

Volume 74, Issue 1, Pages (July 2018)

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

Volume 63, Issue 5, Pages (May 2013)

Volume 71, Issue 5, Pages (May 2017)

Volume 57, Issue 4, Pages e41-e42 (April 2010)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 6, Pages (December 2013)

Volume 73, Issue 2, Pages (February 2018)

Prostate Cancer Epidemic in Sight?

Volume 66, Issue 5, Pages (November 2014)

Global Burden of Urologic Cancers, 1990–2013

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,

Volume 61, Issue 6, Pages (June 2012)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 63, Issue 3, Pages (March 2013)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 59, Issue 1, Pages (January 2011)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Volume 62, Issue 6, Pages (December 2012)

Volume 50, Issue 5, Pages (November 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 72, Issue 4, Pages (October 2017)

Volume 71, Issue 5, Pages (May 2017)

Testicular Cancer Variations in Time and Space in Europe

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 72, Issue 2, Pages (August 2017)

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Volume 72, Issue 1, Pages (July 2017)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Volume 74, Issue 6, Pages (December 2018)

Prostate Cancer 2008: Challenges in Diagnosis and Management

Improving Flexibility and Quality of Life for Your Patients: A Must?

Economic Burden of Bladder Cancer Across the European Union

Volume 53, Issue 6, Pages (June 2008)

Volume 138, Issue 6, Pages (May 2010)

Epidemiology and Demographics of Prostatitis

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 71, Issue 5, Pages 760-763 (May 2017) Validation of a Contemporary Five-tiered Gleason Grade Grouping Using Population- based Data Jianming He, Peter C. Albertsen, Dirk Moore, David Rotter, Kitaw Demissie, Grace Lu-Yao European Urology Volume 71, Issue 5, Pages 760-763 (May 2017) DOI: 10.1016/j.eururo.2016.11.031 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Cumulative incidence of prostate cancer– specific mortality by Gleason grade grouping and treatment. Cumulative incidence data were adjusted by age, race, marital status, region, clinical stage (T1 vs T2 vs T3/T4), diagnosis period (2006–2009 vs 2010–2012), regional lymph node metastasis(N0 vs others), and distant metastasis status (M0 vs others). Other treatments included watchful waiting, active surveillance, and androgen deprivation therapy. European Urology 2017 71, 760-763DOI: (10.1016/j.eururo.2016.11.031) Copyright © 2016 European Association of Urology Terms and Conditions